Research output per year
Research output per year
Fingerprint
Dive into the research topics where Christopher Hourigan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis
Maakaron, J. E., Zhang, M. J., Chen, K., Abhyankar, S., Bhatt, V. R., Chhabra, S., El Jurdi, N., Farag, S. S., He, F., Juckett, M., de Lima, M., Majhail, N., van der Poel, M., Saad, A., Savani, B., Ustun, C., Waller, E. K., Litzow, M., Kebriaei, P., Hourigan, C. S., & 2 others, 2022, (Accepted/In press) In: Bone marrow transplantation.Research output: Contribution to journal › Article › peer-review
-
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Bone Marrow Transplantation, (2021), 56, 12, (3068-3077), 10.1038/s41409-021-01450-3)
Jimenez Jimenez, A. M., De Lima, M., Komanduri, K. V., Wang, T. P., Zhang, M. J., Chen, K., Abdel-Azim, H., Abid, M. B., Aljurf, M., Alkhateeb, H., Assal, A., Bacher, U., Baron, F., Battiwalla, M., Beitinjaneh, A., Bejanyan, N., Bhatt, V. R., Byrne, M., Cahn, J. Y., Cairo, M., & 41 others, May 2022, In: Bone marrow transplantation. 57, 5, p. 852 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt, M. J., Metheny, L., Zhang, M. J., Wang, H. L., Estrada-Merly, N., Marks, D. I., Samer Al-Homsi, A., Muffly, L., Chao, N., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, M., Mussetti, A., Gore, S., Bhatt, V. R., Patel, S. S., Michelis, F. V., Inamoto, Y., Badawy, S. M., & 57 others, Jan 11 2022, In: Blood Advances. 6, 1, p. 339-357 19 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia
Gui, G. & Hourigan, C. S., 2022, In: Cancer Journal (United States). 28, 1, p. 73-77 5 p.Research output: Contribution to journal › Review article › peer-review
-
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D. Y., Ghannam, J. Y., Oetjen, K. A., Destefano, C. B., Smith, D. M., Tekleab, H., Li, Y., Dagur, P., Hughes, T., Marté, J. L., Del Rivero, J., Klubo-Gwiezdzinksa, J., Gulley, J. L., Calvo, K. R., & 2 others, Jan 11 2022, In: Journal for immunotherapy of cancer. 10, 1, e003392.Research output: Contribution to journal › Article › peer-review
Open Access